Levofloxacin

Drug Profile

Levofloxacin

Alternative Names: Cravit Intravenous; Cravit Oral; DR-3355; Levaquin; Levaquin Oral Solution; Tavanic

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Acute sinusitis; Anthrax; Bacterial infections; Community-acquired pneumonia; Nosocomial pneumonia; Pneumonia; Prostatitis; Pyelonephritis; Respiratory tract infections; Sinusitis; Skin and soft tissue infections; Urinary tract infections
  • Registered Gynaecological infections; Postoperative infections; Tuberculosis

Most Recent Events

  • 26 Jul 2016 The US FDA approved label for levofloxacin carries a boxed warning
  • 15 Mar 2016 Biomarkers information updated
  • 24 Sep 2015 Registered for Urinary tract infections, Postoperative infections and gynaecological infections in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top